Could a parasite drug fight childhood brain tumors?

NCT ID NCT01837862

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing whether mebendazole, a drug commonly used to treat intestinal parasites, can help children with brain tumors called gliomas. The study combines mebendazole with standard chemotherapy drugs to see if it is safe and effective. It includes children and young adults up to age 21 with different types of gliomas, including low-grade and high-grade tumors. The goal is to find the best dose of mebendazole and see if it improves survival and slows tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mebendazole, an anti-parasitic drug, given orally twice daily in combination with standard chemotherapy drugs.
What this could lead to
If successful, this could offer a new, well-tolerated addition to standard chemotherapy for pediatric gliomas, potentially improving survival and slowing tumor growth.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. Mebendazole may not improve outcomes, and there is a risk of side effects when combined with other drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cohen Children's Medical Center of New York

    New Hyde Park, New York, 11040, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.